Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Lung Diseases 1Liposarcoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Squamous Cell 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

Radiotherapy 9Doxorubicin 7pazopanib 5palbociclib 4Trabectedin 4Gemcitabine 4ribociclib 3pembrolizumab 3eribulin 3Magnetic Resonance Spectroscopy 3selinexor 2liposomal doxorubicin 2avelumab 2abemaciclib 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Immunoglobulin G 2Ifosfamide 2Docetaxel 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1sotigalimab 1sodium thiosulfate 1sitravatinib 1silmitasertib 1sargramostim 1romidepsin 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liposarcoma × sitravatinib × Clear all
NCT02978859 2024-07-18

Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Columbia University

Phase 2 Completed
29 enrolled 11 charts
Sarcoma

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡